Arcutis Biotherapeutics(US:ARQT) Globenewswire·2025-10-28 12:30Core Insights - Arcutis Biotherapeutics, Inc. is focused on sustainable growth through its innovative dermatology products, particularly the ZORYVE franchise, which has shown significant commercial momentum [2][5][6] Financial Performance - For Q3 2025, Arcutis reported net product revenue of $99.2 million, marking a 122% increase year-over-year and a 22% increase sequentially from Q2 2025 [5][7][9] - The revenue breakdown includes $30.5 million from ZORYVE cream 0.3%, $18.9 million from ZORYVE cream 0.15%, and $49.8 million from ZORYVE topical foam 0.3% [9] - The company anticipates full-year net product sales for 2026 to be between $455 million and $470 million [14] Product Development and Pipeline - ZORYVE is a potent PDE4 inhibitor approved for treating plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with ongoing Phase 2 studies for vitiligo and hidradenitis suppurativa [3][4][6] - The company is also advancing its clinical pipeline with ARQ-234, a potential biologic treatment for atopic dermatitis [8] Cost and Expenses - Cost of sales for Q3 2025 was $8.7 million, up from $5.5 million in Q3 2024, reflecting increased sales of ZORYVE [10] - Research and development expenses remained stable at $19.6 million, while selling, general, and administrative expenses rose to $62.4 million due to increased commercialization efforts [11][12] Profitability - Arcutis achieved a net income of $7.4 million, or $0.06 per share, compared to a net loss of $41.5 million in Q3 2024 [13][24]